| Drug Name: | PREDNISOLONE SODIUM PHOSPHATE |
| Manufacturer: | Bausch & Lomb Incorporated |
| Other Info: | Bausch & Lomb IncorporatedTampa, FL 33637©Bausch & Lomb IncorporatedXO50176 (Folded)XM10030 (Flat)R.12/03-63 |
| Clinical Trials: | |
Prednisolone Sodium Phosphate Ophthalmic Solution 1% or 1/8% is for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation, corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies.Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, is recommended for moderate to severe inflammations, particularly when unusually rapid control is desired.
In stubborn cases of anterior segment eye disease, systemic adrenocortical hormone therapy may be required.
When deeper ocular structures are involved, systemic therapy is necessary.NOT FOR INJECTION INTO EYE - FOR TOPICAL USE ONLYEmployment of steroid medication in the treatment of herpes simplex keratitis involving the stroma requires great caution; frequent slit-lamp microscopy is mandatory.Prolonged use may result in elevated intraocular pressure and/or glaucoma, damage to the optic nerve, defects in visual acuity and fields of vision, posterior subcapsular cataract formation, or may aid in the establishment of secondary ocular infections from pathogens liberated from ocular tissues.
In those diseases causing thinning of the cornea or sclera, perforation has been known to occur with the use of topical steroids.
Acute purulent untreated infection of the eye may be masked or activity enhanced by presence of steroid medication.
Viral, bacterial, and fungal infections of the cornea may be exacerbated by the application of steroids.This drug is not effective in mustard gas keratitis and Sjögren’s keratoconjuncitivitis.If irritation persists or develops, the patient should be advised to discontinue use and consult prescribing physician.